Jul 2026
Abstract A068: Multi-omics validated KRASi-resistant cell lines for combination and sequential drug treatment discovery
Despite the transformative efficacy of KRAS inhibitors in KRAS-mutant malignancies, intrinsic refractoriness and adaptive resistance markedly impair durable treatment responses. Preclinical models that recapitulate the molecular heterogeneity and evolutionary features of clinical resistance are therefore essentia...
Liuxian Meng, Yingxin Bi, Xinuo Zhang et al.
· Clinical Cancer Research · 0 citations